Using RNA technology to improve the production of therapeutic proteins
sxRNA-Select: Using RNAs for Positive Selection of Cell Lines, Enabling High-Yield Biotherapeutic Production
This study is testing a new method to help scientists grow cells that make important medicines more quickly and easily, which could mean patients get access to effective treatments sooner.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sxrna Technologies, INC. NIH-funded |
| Lab location | 1 site (Albany, United States) |
| Project ID | NIH-11077451 on NIH RePORTER |
What this research studies
This research focuses on developing a new technology called sxRNA-Select, which aims to streamline the process of cloning mammalian cells for the production of biologics. By utilizing RNA-based selection methods, the approach seeks to reduce the time and resources needed to identify and cultivate cell lines that produce high yields of therapeutic proteins. Patients may benefit from faster access to effective biologic treatments as this technology could lead to more efficient drug development processes.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals with conditions that require biologic therapies, such as autoimmune diseases or certain cancers.
Not a fit: Patients who do not require biologic treatments or those with conditions that are not addressed by biologics may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly accelerate the production of biologic therapies, making them more accessible to patients.
How similar studies have performed: Other research has shown promise in using RNA-based technologies for cell selection, indicating that this approach may lead to successful advancements in biologic production.
Where this research is happening
Albany, United States
- Sxrna Technologies, INC. — Albany, United States (Active)
Researchers
- Principal investigator: Tenenbaum, Scott — Sxrna Technologies, INC.
- Study coordinator: Tenenbaum, Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.